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ABSTRACT 
Background/Aims.  Genome scanning studies suggest an important role for genes outside the 
major histocompatibility complex in autoimmunity.  Key candidates are those genes involved 
in immune regulation and preservation of immune homeostasis, including the genes involved 
in apoptosis.  Our aim was to determine the association between the Fas gene polymorphism 
at position -670 and susceptibility, clinical expression, and outcome in type 1 autoimmune 
hepatitis.  Methods.  An adenosine to guanine single nucleotide polymorphism in the Fas gene 
(TNFRSF6) promoter was assessed in 149 well-characterised Caucasoid patients and 172 
matched controls.  Results.  Patients and normal subjects had the similar TNFRSF6 -670 allele 
and genotype frequencies.  Serum aspartate aminotransferase (510+77 U/L versus 283+53 
U/L, p=0.01), γ-globulin (3.3+0.2 g/dl versus 2.6+0.2 g/dl), p=0.01), and immunoglobulin G 
(2976+223 mg/dl versus 2324+203 mg/dl, p=0.02) levels were higher in patients with the 
guanine/guanine genotype than in those with the adenosine/adenosine genotype.  Cirrhosis at 
presentation was more common in patients with the adenosine/adenosine or 
adenosine/guanine genotypes than in those with the guanine/guanine genotype (29% versus 
6%, p=0.006; odds ratio=6.4).  Conclusion.  Polymorphism of the Fas gene at position -670 
does not influence susceptibility to autoimmune hepatitis, but may affect the early 
development of cirrhosis. 
 
Key words: Type 1 autoimmune hepatitis, polymerase chain reaction, FAS, TNFRSF6, 
apoptosis, autoimmunity, immune regulation, genetics, complex disease.  
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With an incidence of 1.9 cases per 100,000 per year and a point prevalence of 16.9 
cases 100,000 autoimmune hepatitis (AIH) is a relatively rare chronic liver disease (1). 
Studies suggest however, that it has a strong genetic predisposition, and among Caucasoid 
northern European and North American patients HLA DRB1*0301 and DRB1*0401 are the 
principal, independent, susceptibility alleles (2-4).  Other disease non-specific genetic 
promoters may affect occurrence, clinical expression and outcome of AIH by interactions 
with the major susceptibility alleles (epistasis) or independently (5-9).  Recent studies have 
implicated a polymorphism of the tumor necrosis factor-α gene (TNFA*2) (10, 11) and the 
cytotoxic T lymphocyte antigen-4 gene (CTLA-4) (12) as important factors in the genesis of 
AIH. There are undoubtedly other similar genetic promoters of AIH since none of the 
associations described to date accounts for all instances of disease (8, 9). 
Fas (CD95/Apo-1) is a member of the tumour necrosis factor receptor super-family 
(TNFRSF) of membrane bound molecules that direct receptor mediated programmed cell 
death (apoptosis) (13).  Apoptosis is an essential process in immune homeostasis and 
regulation, and it is particularly important in the termination of immune responses.  Defects in 
the elimination of cells or in the processes participating in the machinery of cell disposal can 
contribute to the breakdown of tolerance and development of autoimmunity (13). 
Recent studies have identified the NOD2 gene, which encodes a member of the Apaf-
1/Ced-1 superfamily of apoptosis regulators, as the first “Crohn’s disease gene” (14-17).  This 
finding highlights the potential importance of apoptosis genes as candidates in complex 
disease.  In Fas and Fas ligand (FasL) knockout mice (lpr/gld), lymphoproliferative disorders 
and spontaneous autoimmune diseases develop that are similar to those seen in humans (18).  
Furthermore, there is evidence that apoptosis contributes to histological activity in AIH (19).  
DNA fragmentation and morphological characteristics of apoptosis are prominent in the 
hepatocytes of patients with AIH; FasL mRNA is increased over levels detected in normal 
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liver; and FasL protein expression is greater than in normal liver and primary biliary cirrhosis 
(19).  Activated T cells play a significant role in the pathogenesis of AIH (20-22), and 
persistence of activated T cells resulting from genetically determined variability in Fas 
expression may be another important event in the induction of autoimmunity (23). 
The gene encoding the Fas molecule has been mapped to chromosome 10q23, and the 
organization of the exons, introns and the promotor region, which includes a single nucleotide 
polymorphism (SNP) at position -670, has been described (24, 25).  Preliminary studies 
indicate that polymorphism at this site influences genetic susceptibility to a number of 
different autoimmune diseases (26, 27), including autoimmune hepatitis (28).  In Japan, the 
Fas polymorphism at position -670 occurs more commonly in patients with AIH than in 
normal subjects, and it is present more frequently in AIH than other Fas polymorphisms (28).  
More recent studies suggest that the FAS-670A polymorphism is associated with higher 
levels of cell surface expression of Fas on activated T cells (29); and that this and other 
Fas and FasL polymorphisms, may be associated with increased activation-induced T 
cell death and susceptibility to cervical cancer (29). Furthermore, it is possible that Fas 
gene (TNFRSF6) polymorphism may act in concert with other autoimmune promoters to 
increase disease risk (30).   
The aims of this study were to determine the distribution of the adenosine (A) to 
guanine (G) SNP at position -670 of the TNFRSF6 gene in a large and well-characterised 
series of Caucasoid patients with type 1 AIH and to assess the relationship between this 
polymorphism and the clinical phenotype of the disease. 
PATIENTS AND METHODS 
Study populations 
One hundred forty-nine patients who fulfilled the diagnostic criteria for AIH 
recommended by the International Autoimmune Hepatitis Group and 172 white adult control 
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subjects constituted the study populations (31).  All patients had the features of type 1 AIH 
with antinuclear antibodies (ANA), smooth muscle antibodies (SMA) or both (32) (Table 1).  
One hundred thirty-five patients (91%) were tested for antibodies to liver/kidney microsome 
type 1 (anti-LKM1), and two were positive (1%) (Table 1). These two patients with anti-
LKM1 also had ANA, including one patient who had SMA and ANA.  They were retained in 
the analysis as patients with type 1 AIH and mixed serological features (32). 
All patients and control subjects were Caucasoid and of northern European 
background.  For patients, the mean age at presentation to the Mayo Clinic was 46±1 years 
(range, 13 to 81 years; median age, 47 years), and 122 were women (82%).  All patients were 
screened for antibodies to hepatitis C virus (anti-HCV) and found to be negative by a second 
generation enzyme linked immunosorbent assay (ELISA) (Ortho Diagnostic Systems, Inc., 
Raritan, New Jersey, USA).  Similarly, all patients were tested and negative for hepatitis B 
surface antigen (HBsAg) by ELISA (Abbott Laboratories, North Chicago, Illinois, USA).  
Fifty-two (35%) had concurrent autoimmune diseases, including autoimmune thyroiditis (21 
patients), inflammatory bowel disease (9 patients), Graves' disease (5 patients), synovitis (3 
patients), Sjogren's syndrome (2 patients), pernicious anemia (2 patients), systemic lupus 
erythematosus (2 patients), and dermatitis herpetiformis, erythema nodosum, focal myositis, 
neuritis, pericarditis, pulmonary fibrosis, rheumatoid arthritis, and systemic sclerosis (one 
patient each).  The clinical features of our study group are detailed in Table 1.  Our study had 
been approved by the Institutional Review Board of the Mayo Clinic. 
Clinical and laboratory assessments 
Each patient underwent a comprehensive clinical review and complete physical 
examination at presentation and at each follow-up visit by one investigator (A.J.C.).  
Conventional laboratory tests of liver inflammation and function were assessed in a uniform 
fashion.  Concurrent diseases of a presumed autoimmune nature were sought systematically in 
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each patient in accordance with a previously published protocol (33, 34). 
Smooth muscle antibodies were sought by indirect immunofluorescence (IF) on 
murine tissue sections (149 patients) (35); ANA were determined either by IF (147 patients) 
(35) or ELISA (2 patients) (36); and anti-LKM1 were sought by IF on murine tissue sections 
(135 patients) (32, 35) (Table 1). 
Treatment regimens 
One hundred thirty-five patients (91%) were treated with prednisone in combination 
with azathioprine (87 patients) or a higher dose of prednisone alone (48 patients).  These 
regimens had been shown previously to be of comparable efficacy (37), and outcomes were 
analyzed only in individuals treated in this fashion.  Thirteen patients received no medication, 
and one patient was treated with an investigational drug.  Outcomes in these 14 individuals 
were not included in the analysis. 
Treatment was continued until remission, treatment failure, or drug intolerance (37).  
Remission connoted absence of symptoms, resolution of laboratory abnormalities, except for a 
less than two-fold elevation of the serum aspartate aminotransferase (AST), and improvement 
of histological findings to normal, inactive cirrhosis, or nonspecific inflammation.  Treatment 
failure connoted clinical, laboratory and/or histological worsening despite compliance with 
treatment.  Recrudescence of inflammatory activity after remission and drug withdrawal 
indicated a relapse, and continued inactivity after remission and drug withdrawal connoted a 
sustained remission.  All patients were followed in a uniform fashion for 104+8 months 
during and after therapy. 
Histological assessment 
Liver tissue was obtained at presentation by percutaneous needle biopsy in 146 
patients (98%).  Tissue samples were interpreted in accordance with previously published 
criteria (38, 39), and specimens were interpreted under code by experienced liver pathologists.  
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The diagnosis of cirrhosis required fibrosis and the presence of a complete regenerative 
nodule (38, 39).  Our previous validation studies have indicated that the consistency of 
pathological interpretation for grade (90%) and stage of disease (78%) using pre-established 
definitions for the histological findings is high and that the reproducibility of the histological 
interpretation is 94% (38, 39).  Thirty-four patients had cirrhosis at accession.  Of the 112 
patients who did not have histological evidence of cirrhosis at accession, 82 (73%) had a 
subsequent liver biopsy examination.  These patients were analyzed to determine the 
frequency of progression to cirrhosis after treatment. 
HLA determinations 
All patients were genotyped for HLA DRB1, DQA1 and DQB1 as part of previously 
published studies, and class I HLA (A and B loci) were determined in all patients by a 
standard microlymphocytoxicity technique (3, 9). HLA data are not shown in this 
manuscript. 
Determination of TNFRSF6 polymorphism 
A 332 bp fragment of the TNFRSF6 gene promoter containing the A to G SNP at 
position –670 was amplified using the primers 5’-CTACCTAAGAGCTATCTACCGTTC-3’ 
(sense) and 5’-GGCTGTCCATGTTGTGGCTGC-3’ (antisense).  The 25µl reaction mixture 
contained a 1X concentration of commercial reaction buffer (ABgene, UK, buffer II) and 200 
nM of each dNTP, 1µM of each primer, 1mM MgCl2, 50-200ng genomic DNA, and 2.5U of 
Taq polymerase (ABgene, UK).  Amplification was performed in a Perkin-Elmer Cetus 
GeneAmp 9700 system thermocycler (Perkin-Elmer Cetus, Warrington, UK).  Cycling 
parameters were as follows: initial denaturation for 5 minutes at 94°C followed by 35 cycles at 
94°C for 30 seconds, 62°C for 30 seconds, 72°C for 30 seconds, and a final extension at 72°C 
for 10 minutes. 
Following amplification, a 15 ul aliqout of the amplicon was digested with 5 units of 
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the restriction endonuclease Mva I (Roche, UK) under recommended conditions for a 
minimum of 5 hours at 37°C.  This restriction enzyme recognises the sequence, CCAGG, and 
digestion results in cleavage of the polymerase chain reaction (PCR) amplicon.  Since all 
amplicons encode this sequence at position -858, digestion of the 331 bp PCR-amplicon 
results in at least two fragments of 232 and 99 bp.  However, if the amplicon encodes G at 
position –670, a second restriction site is present and the 232 bp fragment will be cleaved into 
two further fragments of 189 and 43 bp (Figure 1). Thus, three different TNFRSF6 genotypes 
were identified under ultraviolet transillumination following separation of the digested PCR-
amplicons by electrophoresis on 2 percent (w/v) agarose gels stained with ethidium bromide.  
The three genotypes were as follows: GG (43 bp+189 bp+99 bp), AG (43 bp+99 bp+189 
bp+232 bp) and AA (99 bp+232 bp only).  Control samples of pre-determined genotypes and 
negative controls (no DNA added) were included in each sample batch. 
Statistical analysis 
Allele and genotype frequencies were compared using χ2 and Fisher’s exact 
probability tests as appropriate.  All analyses were performed on a personal computer using 
the Epistat statistical software (Epi-info, CDC, Atlanta, Georgia, USA).  Clinical differences 
were sought using the unpaired t test to evaluate continuous variables, and the Fisher’s exact 
probability test for comparison of dichotomous variables.  The Mann-Whitney test was used 
to compare non-parametric variables in independent samples. Since the variables for 
comparison had been formulated a priori and then assessed systematically in each study 
group, an unadjusted p-value of 0.05 was used to determine statistical significance.  Data are 
presented as the mean+standard error of the mean in tables and text. 
RESULTS 
Frequency of TNFRSF6 genotypes 
The observed genotype frequencies for both patients and controls were in Hardy-
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Weinberg equilibrium (Table 2).  There were no significant differences in the distribution of 
the genotypes; AA, AG or GG, or alleles A and G comparing patients and controls.   
TNFRSF6 genotypes and clinical features 
Patients with the GG or AG genotype had significantly higher serum AST, γ-globulin, 
and immunoglobulin G levels at presentation than those with the AA genotype (Table 3).  
Otherwise, there were no differences between the TNFRSF6 genotypes in age at presentation, 
gender distribution, pattern and frequency of serum autoantibodies, or occurrence of 
extrahepatic autoimmune diseases (Table 3).  
TNFRSF6 genotypes and treatment outcome 
TNFRSF6 genotypes did not affect treatment outcome among the 138 patients who 
received conventional therapy and were followed for a similar duration (Table 4).  The 
frequencies of remission, treatment failure and incomplete response were comparable in all 
genotypes.  Progression to cirrhosis; death from liver failure and requirement for liver 
transplantation were also similar in all groups.  Patients with the AA genotype had a higher 
frequency of sustained remission (36% versus 14%, p=0.2) and lower occurrence of relapse 
(64% versus 86%, p=0.2) after treatment withdrawal than patients with the GG genotype, but 
these differences were not statistically significant (Table 4). 
TNFRSF6 genotypes and cirrhosis 
Patients with the AA or AG genotype were more likely to have cirrhosis at 
presentation than those with the GG genotype (Table 3).  Thirty-three percent of those with 
the AA genotype and 26% of those with the AG genotype had cirrhosis at accession compared 
with only 6% of those with the GG genotype (Table 3, p=0.006, OR = 6.4).  The highest risk 
for cirrhosis at presentation was in patients with the AA genotype (p=0.0029, OR = 8.3), 
whereas patients with the AG genotype had a lower but still significantly increased risk 
compared to patients with the GG genotype (p=0.015, OR = 5.5).  Patients with and without 
Second Revision - Agarwal et al. Fas gene in AIH 10 
cirrhosis at presentation were not otherwise distinguishable (Table 5). 
DISCUSSION 
Our study indicates that the –670 A/G SNP in the promoter region of the TNFRSF6 
gene is associated with an increased frequency of histologically defined cirrhosis at 
presentation in patients with type 1 AIH.  Indeed, patients with the AG or AA genotypes 
presented in this fashion approximately 6 and 8 times more commonly than patients with the 
GG genotype.  In contrast, patients with genotypes including the G allele (either AG or GG) 
had higher serum concentrations of AST, γ-globulin and immunoglobulin G at presentation 
(Table 3).  These laboratory findings reflected a greater degree of liver inflammation in these 
individuals, possibly because of more vigorous immune reactivity.  Furthermore, our patients 
with the GG genotype have a lower frequency of sustained remission and higher occurrence 
of relapse after drug withdrawal than the other genotypes, albeit these latter differences were 
not statistically significant (Table 4).  
The apparent discordance between the frequency of cirrhosis and the laboratory 
indices of liver injury in patients with different genotypes is difficult to explain.  One possible 
explanation is that patients with the GG genotype presented for treatment earlier than patients 
with the AA and AG genotypes because of their increased inflammatory activity.  Patients 
with the GG genotype may thereby have been treated earlier in their course and been 
protected from progression to cirrhosis.  Progression to cirrhosis in type 1 AIH is closely 
related to inflammatory activity, and early treatment and rapid suppression of the 
inflammatory process can prevent or reduce hepatic fibrosis (39). 
The differences in the frequencies of sustained remission and relapse after drug 
withdrawal were not statistically significant between the patients with the various genotypes 
(Table 4), and we must be careful not to over-interpret the observed trends.  Even if the 
differences in sustained remission and relapse between the genotypes had been statistically 
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significant, previous studies have not indicated that relapse and re-treatment after initial 
therapy are associated with an increased risk of developing cirrhosis or liver failure (40, 41).  
Indeed, the low biochemical threshold for declaring relapse (serum aspartate aminotransferase 
level >three-fold the upper limit of normal) and prompt institution of corticosteroid therapy 
may actually prevent or decrease fibrosis (39, 42). Furthermore, the major association of the 
GG genotype was in the reduced frequency of cirrhosis at presentation (not in the 
development of cirrhosis after treatment) compared to the other genotypes, suggesting that the 
GG genotype influences the natural history of the disease rather than its responsiveness to 
treatment. 
Autoimmune hepatitis is commonly associated with several concurrent immune 
diseases, and the prevailing hypothesis is that these diverse immune-mediated diseases reflect 
a genetic propensity for heightened immune reactivity and a promiscuous immune response 
against homologous epitopes in different organs (43). Our study does not indicate an 
association between the TNFRSF6 genotype and a particular clinical subgroup with a 
concurrent immune disease. However, we cannot entirely exclude the possibility that clinical 
heterogeneity in the expression of certain autoimmune features has in some way contributed 
to the lack of an association between TNFRSF6 genotype and this disease. Future studies 
must evaluate the impact of the Fas genotypes in larger numbers of patients with autoimmune 
hepatitis alone and in those with different types of concurrent immune diseases to make this 
determination. 
Apoptosis is an important mechanism for the maintenance of immune homeostasis and 
in particular for termination of effector mechanisms of the immune response (13, 18, 44, 45).  
Fas and FasL are the primary inducers of membrane induced (receptor-mediated) cell death.  
Administration of anti-Fas antibody in mice induces massive cell loss and hepatic failure (46), 
and there is increasing evidence that apoptosis contributes to liver injury, especially in 
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alcoholic liver disease, viral hepatitis and in autoimmune liver disease (47-51).  Apoptosis in 
the liver is responsible for elimination of activated CD4+ effector cells via the Fas-FasL 
pathway and suppression of interferon-gamma producing cells (52).  Thus, apoptosis in the 
liver may play a role in antigen presentation and induction of tolerance by influencing the 
nature and durability of immunocyte activation (53-55).  Current evidence suggests that the -
670 A/G SNP is associated with increased nuclear factor STAT1 binding activity and that 
the -670A allele, in particular, is associated with higher levels of Fas expression on 
activated T cells (29, 56).  It may therefore have a functional role in the apoptotic cascade 
and in turn influence disease severity in type 1 AIH. 
Currently the functional significance of the Fas genotypes in not fully understood.  
Since Fas-FasL mediated apoptosis is directed at both parenchymal and non-parenchymal 
cells within the liver, possession of the GG genotype may facilitate apoptosis of damaged 
hepatocytes, and this action may result in greater disturbances of the laboratory indices that 
reflect increased hepatocyte loss.  Hepatic stellate cells also undergo apoptosis (55, 56), and 
the GG genotype may protect against cirrhosis by favoring the elimination of these cells.  In 
contrast, the AA or AG genotype may favor the prolonged survival of immunocytes and other 
non-parenchymal cells, including fibroblasts and hepatic stellate cells, and in this fashion, 
increase the likelihood of significant fibrosis (57). 
Importantly, the TNFRSF6 genotype does not correlate with treatment outcome.  Our 
previous studies have indicated that patients with cirrhosis respond as well to corticosteroid 
therapy as patients with similar disease activity without cirrhosis (58, 59).  Accordingly, all 
patients regardless of histological findings at presentation would be expected to respond to 
treatment.  The greater degrees of inflammation and/or immune activity at presentation in our 
patients with the GG genotype did not translate into a poorer treatment response.  Our 
findings suggest that the TNFRSF6 genotype influences the natural history of the disease 
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rather than its behaviour after therapy. 
In mice, “loss of function” mutations in both the Fas and FasL genes, lpr and gld, 
result in autoimmune phenomena including; hypergammaglobulinemia, lymphadenopathy and 
splenomegaly. The equivalent in human subjects is the Canale-Smith syndrome (CSS) which 
is characterised by hypergammaglobulinemia, systemic autoimmunity, lymphadenopathy and 
splenomegaly (60). Affected patients have abnormal T lymphocyte apoptosis which correlates 
with various heterozygous mutations of the TNFRSF6 gene.  A similar clinical phenotype is 
seen in autoimmune lymphoproliferative syndrome (ALPS) where abnormalities in apoptosis 
have been reported in both patients and their unaffected relatives (61, 62). Apoptosis may also 
play a role in revealing hitherto cryptic autoantigens or epitopes by substrate cleavage.  Such 
cryptic epitopes or antigens may have initially evaded tolerance induction by being hidden 
from immunocytes during ontogeny (63). 
In our study, we have identified an association between a functional SNP in the 
promoter region of the Fas gene and increased risk of cirrhosis in untreated type 1 AIH.  
Current evidence suggests that this SNP may also be associated with disease severity in 
systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) (26) and that A/G SNP 
correlates with increased nuclear factor STAT1 binding activity (54).  Situated on a consensus 
region of the gamma-activated sequence (GAS), this SNP may thus influence the transcription 
of several immunoregulatory proteins in addition to Fas (64).  Alternatively the TNFRSF6 
SNP may simply be a marker for another gene or genes on chromosome 10q23, including 
other SNP’s within the TNFSRF6 itself (65), which may influence disease severity in type 1 
AIH.  Functional studies of the AA and AG SNPs are necessary to validate our finding that 
they are associated with an increased risk of cirrhosis. 
The wider implications of this study suggest that investigation of the genetic 
influences on the apoptotic cascade may be relevant to the pathogenesis of autoimmunity.  
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Given the degree of redundancy in this essential biological process, it is likely that any 
contribution to genetic susceptibility is a composite effect of many different SNPs.  In the 
post-genome era, the challenge for investigators of complex disease genetics will be to focus 
on biologically relevant processes and assess serial rather than single SNPs and serial rather 
than single genes within these pathways. 
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Table 1 
Clinical Features of Study Population (N=149) 
Clinical Features Findings 
 
Age (years) 
 
46+1 
 
Female:male 
 
122:27 
Concurrent immune diseases 
 
52 (35) 
AST (nl, <31 U/L) 
 
428+34 
Bilirubin (nl, <1.1 mg/dl) 
 
3.8+0.4 
γ-globulin (nl, 0.7-1.7 g/dl) 
 
2.9+0.1 
Immunoglobulin G (nl, 700-1500 mg/dL) 
 
2712+114 
SMA and/or ANA 
 
149 (100) 
Anti-LKM1>1:10 
 
2/135 (1) 
Cirrhosis at entry 
 
34/146 (23) 
Numbers in parentheses are percentages. 
AST = serum aspartate aminotransferase level. 
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Table 2 
Frequency of TNFRSF6 Genotypes in Autoimmune Hepatitis and Normal Subjects 
TNFRSF6 genotype Autoimmune hepatitis 
(N=149) 
 
Normal subjects 
(N=172) 
 
AA 
 
39 (26) 56 (33) 
AG 
 
75 (50) 84 (49) 
GG 35 (23) 32 (19) 
 
A – allele frequency 
 
0.513 0.567 
G – allele frequency 
 
0.486 0.430 
Numbers in parentheses are percentages. 
AA = adenosine/adenosine genotype of TNFRSF6; AG = adenosine/guanine genotype of 
TNFRSF6; GG = guanine/guanine genotype of TNFRSF6. 
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Table 3 
Clinical Features and TNFRSF6 Genotypes 
Clinical Features TNFRSF6 Genotypes 
 
 AA 
(N=39) 
AG 
(N=75) 
GG 
(N=35) 
 
AG or GG 
(N=110) 
 
Age (years) 
 
43+3 49+2 44+3 47+2 
Female:male 
 
31:8 61:14 30:5 92:19 
Concurrent immune diseases 
 
14 (36) 25 (33) 13 (37) 39 (35) 
• Thyroid disease 
 
9 (23) 10 (13) 7 (20) 17 (15) 
• Inflammatory bowel disease 
 
3 (8) 5 (7) 1 (3) 6 (5) 
• Rheumatic diseases 
 
1 (3) 6 (8) 4 (11) 10 (9) 
AST 
(nl, <31 U/L) 
 
283+53b,c,e 464+48e 510+77c 475+41b 
Bilirubin 
(nl, <1.1 mg/dl) 
 
3.5+0.8 3.8+0.6 3.9+0.7 3.8+0.5 
γ-globulin 
(nl, 0.7-1.7 g/dl) 
 
2.6+0.2d,i 3.0+0.1 3.3+0.2d 3.0+0.1i 
IgG (nl, 700-1500 mg/dl) 
 
2324+203f,g 2776+167 2976+223f 2819+134g 
SMA>1:40 only 
 
14 (36) 16 (21) 7 (20) 23 (21) 
ANA>1:40 only 
 
8 (20) 21 (28) 9 (26) 30 (27) 
SMA+ANA>1:40 
 
17 (44) 38 (51) 19 (54) 57 (52) 
Cirrhosis at entry 
 
13 (33)a 19/73 (26)h 2/34 (6)a,h 21/108 (19) 
Significantly different from each other at level of ap=0.0029 OR = 8.3, bp=0.007, c,dp=0.01, 
e,f,gp=0.02, and hp=0.015 OR = 5.5. 
 
Numbers in parentheses are percentages.  AA = adenosine/adenosine genotype of TNFRSF6; 
AG = adenosine/guanine genotype of TNFRSF6; GG = guanine/guanine genotype of 
TNFRSF6; AST = serum aspartate aminotransferase level; IgG = serum immunoglobulin G 
level; SMA = smooth muscle antibodies; ANA = antinuclear antibodies. 
 
Rheumatic diseases included systemic lupus erythematosus, systemic sclerosis, rheumatoid 
arthritis, synovitis, myositis, pericarditis, Sjogren’s syndrome, and neuritis. 
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Table 4 
TNFRSF6 Genotypes and Treatment Outcome 
Outcome TNFRSF6 Genotypes 
 
 AA 
(N=35) 
AG 
(N=71) 
GG 
(N=32) 
 
Remission 
 
22 (63) 50 (70) 22 (69) 
Sustained remission 
 
8/22 (36) 14/50 (28) 3/22 (14) 
Relapse 
 
14/22 (64) 35/50 (70) 19/22 (86) 
Treatment failure 
 
4 (11) 9 (13) 4 (12) 
Continuous treatment 
 
9 (26) 12 (17) 6 (19) 
Developed cirrhosis 
 
4/16 (25) 13/40 (32) 8/24 (33) 
Liver transplantation 
 
2 (6) 4/76 (5) 2 (6) 
Death from hepatic failure 
 
3 (9) 2/76 (3) 0 (0) 
Transplantation or hepatic 
death 
 
5 (14) 6/76 (8) 2 (6) 
Death (total) 
 
4 (11) 6/76 (8) 3 (9) 
Duration follow-up (mo) 
 
106+16 114+12 90+15 
Numbers in parentheses are percentages. 
AA = adenosine/adenosine genotype of TNFRSF6; AG = adenosine/guanine genotype of 
TNFRSF6; GG = guanine/guanine genotype of TNFRSF6. 
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Table 5 
Clinical Features of Patients With and Without Cirrhosis at Entry 
 
Features At Entry Cirrhosis At Entry 
(N=34) 
 
No Cirrhosis At Entry 
(N=112) 
Age (years) 
 
49+2 45+2 
Female:male 
 
27:7 94:18 
Concurrent immune diseases 
 
13 (38) 37 (33) 
Duration symptoms prior to 
entry (mo) 
 
42+9 32+5 
AST 
(nl, <31 U/L) 
 
314+54 466+41 
Bilirubin 
(nl, <1.1 mg/dl) 
 
3.9+0.9 3.5+0.4 
γ-globulin 
(nl, 0.7-1.7 g/dl) 
 
2.9+0.2 3.0+0.1 
IgG 
(nl, 700-1500 mg/dl) 
 
2557+219 2752+132 
Number is parentheses are percentages. 
AST = serum aspartate aminotransferase level; IgG = serum immunoglobulin G level; AA = 
adenosine/adenosine genotype of TNFRSF6; GG = guanine/guanine genotype of TNFRSF6; 
AG = adenosine/guanine genotype of TNFRSF6. 
 
